fluorofuranylnorprogesterone
Small moleculeexperimentalImaging agent
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jul 15, 2017 (NCT03212170)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Androgen ReceptorRadiopharmaceutical
AR radiopharmaceutical
Chemistry & pharmacology
Loading structure…
SMILES
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@H]43)[C@@H]1C[C@H]1O[C@@H](c3ccco3)O[C@]12C(=O)CF- Mol. weight
- 428.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL378031 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06067503 | Phase 2 | Jan 31, 2024 | University of Wisconsin |
| NCT06086704 | Phase 2 | Jan 31, 2024 | National Cancer Institute (NCI), University of Wisconsin |
| NCT05480995 | Phase 2 | Dec 31, 2022 | National Institutes of Health (NIH), University of North Carolina at Chapel Hill |
| NCT05483023 | Phase 2 | Sep 8, 2022 | Radiological Society of North America, University of North Carolina at Chapel Hill |
| NCT03212170 | Phase 2 | Jul 15, 2017 | University of Wisconsin |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Wisconsin | Academic/Hospital | 3 | 3 | 1 | 2017 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 2 | 2 | 1 | 2022 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2024 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2022 |
| Radiological Society of North America | Academic/Hospital | 1 | 0 | 1 | 2022 |
5 organizations
Page 1 / 1